Soligenix Inc. (SNGX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.38 (+0.32%), Market cap $0.01B, 52-week low–high $0.28 ~ $4.96.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulce
Financial statements, price targets, institutional (13F) holdings and related news for Soligenix Inc. are updated in real time on BlackAll Trade.
Soligenix Inc. trades at $0.38 (+0.32%). Real-time quotes and charts are available on BlackAll Trade.
Soligenix Inc. has a market cap of about $0.01B.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segm